Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07455903 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Assessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA PET/CT

StatusRecruiting
PhasePhase 2
Started2026-07-29
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 3 months later Oct 2029 → Feb 2030
See other at-risk trials from Baptist Health South Florida

Amendment history

2026-08-04
Study Status v2
Primary completion pushed: 2029-10 → 2030-02
Completion pushed: 2030-10 → 2031-02
Start date2026-04-23→2026-07-29
2026-05-12
Study Status, Contacts/Locations v1
Recruitment opened
Start dateestimated 2026-04→confirmed 2026-04-23
Study sitesdetails revised at 1 of 1 site
2026-03-03
Original filing
The purpose of this research study is to test the efficacy of ADT on prostate-specific membrane antigen (PSMA), a marker of prostate cancer, before and after scheduled ADT. Follow up will be 48 months your prostate removal to do a blood test and log if any new or worsening symptoms have occurred as a part of your standard-of-care (SOC).
Trial Details
NCT Number NCT07455903
Lead Sponsor Baptist Health South Florida
Collaborators: Blue Earth Diagnostics
Conditions Prostate Cancer, Localized Prostate Carcinoma
Enrollment 50 participants
Start Date 2026-07-29
Primary Completion 2030-02 (estimated)
Study Completion 2031-02 (estimated)
Updated on ClinicalTrials.gov 2026-08-06